[1. Boonpasart S, Kasetsuwan N, Puangsricharern V, Pariyakanok L, Jittpoonkusol T. Infectious keratitis at King Chulalongkorn Memorial Hospital: a 12-year retrospective study of 391 cases. J Med Assoc Thai. 2002; 85:217S-30S.]Search in Google Scholar
[2. American Academy of Ophthalmology Vision Rehabilitation Panel. Preferred Practice Pattern® Guidelines. Bacterial Keratitis. San Francisco: American Academy of Ophthalmology; 2008. Available at: http://www.aao.org/ppp.]Search in Google Scholar
[3. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991; 112:34S-47S.]Search in Google Scholar
[4. O’Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995; 113:1257-65.10.1001/archopht.1995.01100100045026]Open DOISearch in Google Scholar
[5. Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a doublemasked, randomized, controlled trial with conventional dual therapy. Ophthalmology. 1997; 104:1902-9.10.1016/S0161-6420(97)30009-8]Search in Google Scholar
[6. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004; 49:73S-8S.10.1016/j.survophthal.2004.01.005]Search in Google Scholar
[7. Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol. 2007; 55:15-9.10.4103/0301-4738.29489]Open DOISearch in Google Scholar
[8. Jones DB. Decision making in the management of microbial keratitis. Ophthalmology. 1981; 88:814-20.10.1016/S0161-6420(81)34943-4]Open DOISearch in Google Scholar
[9. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye. 1999; 13:744-7.10.1038/eye.1999.220]Search in Google Scholar
[10. Gangopadhyay N, Daniell M, Weih L, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol. 2000; 84: 378-84.10.1136/bjo.84.4.378]Open DOISearch in Google Scholar
[11. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolones resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-8.10.1016/S0161-6420(99)00716-2]Search in Google Scholar
[12. Daniell M. Overview: initial antimicrobial therapy for microbial keratitis. Br J Ophthalmol. 2003; 87:1172-4.10.1136/bjo.87.9.1172177182712928292]Search in Google Scholar
[13. Parmar P, Salman A, Kalavathy CM, Kaliamurthy J, Prasanth DA, Thomas PA, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006; 141:282-6.10.1016/j.ajo.2005.08.08116458681]Search in Google Scholar
[14. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology. 2007; 114:1622-9.10.1016/j.ophtha.2006.12.011]Open DOISearch in Google Scholar
[15. Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin. 2007; 23: 2955-60.10.1185/030079907X242728]Search in Google Scholar
[16. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003; 136:500-5.10.1016/S0002-9394(03)00294-0]Search in Google Scholar
[17. Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humor levels of topically applied levofloxacin in human eyes. Curr Eye Res. 2002; 24: 403-6.10.1076/ceyr.24.5.403.8517]Open DOISearch in Google Scholar
[18. Colin J, Simonpoli S, Geldsetzer K, Ropo A. Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. Acta Ophthalmol Scand. 2003; 81:611-3.10.1111/j.1395-3907.2003.00173.x]Open DOISearch in Google Scholar
[19. Bucci FA Jr. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol. 2004; 137: 308-12.10.1016/j.ajo.2003.08.057]Search in Google Scholar
[20. Healy DP, Holland EJ, Nordlund ML, Dunn S, Chow C, Lindstrom RL, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004; 23:255-63.10.1097/00003226-200404000-00007]Open DOISearch in Google Scholar
[21. Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001; 131:131-3.10.1016/S0002-9394(00)00642-5]Open DOISearch in Google Scholar
[22. Tanhehco TY, Chiavetta SV 3rd, Lee PP, Fowler AM, Afshari NA. “Cracked-mud” ciprofloxacin precipitates on a corneal graft. Ophthalmic Surg Lasers Imaging. 2005; 36:252-3.10.3928/1542-8877-20050501-14]Search in Google Scholar
[23. Awwad ST, Haddad W, Wang MX, Parmar D, Conger D, Cavanagh HD. Corneal intrastromal gatifloxacin crystal deposits after penetrating keratoplasty. Eye Contact Lens. 2004; 30:169-72.10.1097/01.ICL.0000133241.56713.2F15499240]Open DOISearch in Google Scholar
[24. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, Puangsricharern V, Pariyakanok L. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai. 2004; 87:83S-90S. ]Search in Google Scholar